Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
MicroPort Scientific ( (HK:0853) ) has shared an announcement.
MicroPort Scientific Corporation’s subsidiary, Shanghai MicroPort Endovascular MedTech, has reported expected revenue growth for the year ending December 2024, with figures between RMB1,187.5 million and RMB1,306.0 million, marking an increase of up to 10.01% compared to the previous year. The company’s innovative product offerings have bolstered momentum, although market changes and strategic pricing adjustments have impacted growth rates. Additionally, the company has increased its overseas market revenue, reflecting a strategic focus on international expansion.
More about MicroPort Scientific
MicroPort Scientific Corporation is a company incorporated in the Cayman Islands, operating in the medical technology industry. It focuses on developing innovative medical devices, particularly in the endovascular sector, with a significant market presence in China and expanding efforts overseas. Key products include stent grafts and drug balloon dilatation catheters.
YTD Price Performance: -3.69%
Average Trading Volume: 40,591
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: $1.3B
For detailed information about 0853 stock, go to TipRanks’ Stock Analysis page.
